Choudhary Narendra S, Dhampalwar Swapnil, Saraf Neeraj, Soin Arvinder S
Institute of Liver Transplantation and Regenerative Medicine, Medanta the Medicity, Gurgaon, Delhi (NCR), India.
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):713-719. doi: 10.1016/j.jceh.2021.05.003. Epub 2021 May 12.
Coronavirus disease 2019 (COVID-19) is associated with a significant morbidity and mortality in patients with cirrhosis. There is a significantly higher morbidity and mortality due to COVID-19 in patients with decompensated cirrhosis as compared to compensated cirrhosis, and in patients with cirrhosis as compared to noncirrhotic chronic liver disease. The fear of COVID-19 before or after liver transplantation has lead to a significant reduction in liver transplantation numbers, and patients with decompensated cirrhosis remain at risk of wait list mortality. The studies in liver transplantation recipients show that risk of mortality due to COVID-19 is generally driven by higher age and comorbidities. The current review discusses available literature regarding outcomes of COVID-19 in patients with cirrhosis and outcomes in liver transplant recipients.
2019冠状病毒病（COVID-19）与肝硬化患者的高发病率和死亡率相关。与代偿期肝硬化患者相比，失代偿期肝硬化患者因COVID-19导致的发病率和死亡率显著更高；与非肝硬化慢性肝病患者相比，肝硬化患者因COVID-19导致的发病率和死亡率也显著更高。肝移植前后对COVID-19的恐惧导致肝移植数量大幅减少，失代偿期肝硬化患者仍面临等待名单死亡风险。对肝移植受者的研究表明，COVID-19导致的死亡风险通常由高龄和合并症驱动。本综述讨论了关于肝硬化患者COVID-19的预后以及肝移植受者预后的现有文献。
